Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2010

View Archived Issues

Preclinical and clinical data presented on antibiotic CB-183315

Lundbeck describes new neuropeptide Y5 receptor antagonists

U.S. scientists claim new MAPK 8 inhibitors

MorphoSys and Proteros Biostructures receive grant to develop new technology platform

Biotie regains rights to phosphodiesterase 10 inhibitors for CNS disorders

Phase I data reported on Zealand Pharma's ZP-1848 in Crohn's disease

Phase I trials assess safety, tolerability and pharmacokinetics of ASM-024

DCVax-L is well tolerated combined with other anticancer agents in ovarian cancer

PEGylated opioid analgesic NKTR-181 demonstrates slowed entry into CNS

Tekmira receives grant to develop RNAi agents against Ebola and Marburg virus infections

Genmab reports feedback from U.S. and E.U. authorities on zalutumumab

EC grants orphan drug status for pralatrexate in Hodgkin's lymphoma

Labopharm and Paladin Labs enter agreements on pain medications

Amgen reviews TREAT data and proposes updates to ESA labeling

New protein kinase inhibitors identified by sanofi-aventis

FDA approves ISTA's sNDA for bromfenac ophthalmic solution Bromday

Inhibitex completes enrollment in phase II FV-100 trial in shingles

New inhibitors of dual specificity protein kinase TTK claimed

Glenmark Pharmaceuticals patents new TRPA1 modulators

FDA approves Botox as treatment for chronic migraine

Celgene acquires Abraxis BioScience

EMA grants orphan drug status for forodesine in chronic lymphocytic leukemia

Phosphagenics to advance TPM oxycodone patch

New selective serine/threonine-protein kinase 6 inhibitors discovered

Levetiracetam does not improve cerebellar symptoms of multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...